Please provide your email address to receive an email when new articles are posted on . Administering a once-yearly infusion of zoledronic acid within 90 days after the surgical repair of a low-trauma ...
To earn CME related to this news article, click here. April 20, 2009 — A single 5-mg intravenous infusion of zoledronic acid was at least as effective and more acceptable to patients than 5 mg of oral ...
Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...
June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...
Zoledronic acid, while a bisphosphonate itself, is much more potent, and needs only to be given in a once-yearly infusion. In this randomised controlled trial, Professor David M Reid, University of ...
(HealthDay News) – For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a ...
Comparison of Diameter and Perimeter Methods for Tumor Volume Calculation PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to ...
A single infusion of zoledronic acid reduces fracture risk for more than 1 year, new data suggest. Annual infusions of zoledronic acid reduce fracture risk in postmenopausal women with osteoporosis.
SCHAUMBURG, Ill., February 18, 2025--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid ...
A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, ...
Paracetamol taken for 3 days reduces post-dose symptoms related to zoledronic acid infusion, new research reveals. Transient post-dose symptoms, including fever and myalgia, may occur following the ...
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results